⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 1, 2024Open Access

Supplementary Figure S1 from Disparities in OncotypeDx Testing and Subsequent Chemotherapy Receipt by Geography and Socioeconomic Status

Sarah C. Van Alsten Matthew R. Dunn Alina M. Hamilton Joannie M. Ivory Xiaohua Gao Erin L. Kirk Joseph Nsonwu-Farley Lisa A. Carey Yara Abdou Katherine E. Reeder‐Hayes Mya L. Roberson Stephanie B. Wheeler Marc A. Emerson Terry Hyslop Melissa A. Troester

View Full Paper

Ask AI

Bookmark

Share

Abstract

Supplementary Figure S1 depicts geographic differences in OncotypeDx testing across the state of North Carolina. It also shows the magnitude of racial disparities by region within the state.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Alsten et al. (2024) studied this question.

synapsesocial.com/papers/68e6c4b3b6db6435876434e5 https://doi.org/10.1158/1055-9965.25729141.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S1 from Disparities in OncotypeDx Testing and Subsequent Chemotherapy Receipt by Geography and Socioeconomic Status2024
2Data from Disparities in OncotypeDx Testing and Subsequent Chemotherapy Receipt by Geography and Socioeconomic Status2024
3Racial disparities in initiation of chemotherapy among breast cancer patients with discretionary treatment indication in the state of Georgia2024 · 3 citations
4Abstract PS4-12-08: Oncotype DX prediction of recurrence by racecohort · 2026
5Addressing Social Determinants in the Era of Precision Medicine in Breast Cancer: Is It Sufficient to Reduce Disparities?2024 · 1 citations

More related papers

Abstract A055: Neighborhood Deprivation and Oncotype DX Recurrence Scores among Black and White Women: the interplay between race, place, and tumor biology2024
Data from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy2024
Abstract PS4-11-16: Treatment Delays and Testing Disparities May Contribute to Racial Differences in Node-Positive ER+/HER2- Breast Cancer Outcomes2026